Keywords: blood-retinal barrier, VEGFA165b, MAPK, AKT, Endothelial blood-retinal barrier, diabetic retinopathy, image analysis, optical coherence tomography, retinal cell culture, retinal vasculature 2 ABSTRACT Purpose: Studies show that the b-isoform of Vascular Endothelial Growth Factor-A-165 (VEGFA 165 b) is predominant in normal human vitreous, switching to the a-isoform (VEGFA 165 a) in the vitreous of eyes with active diabetic retinopathy or ROP. The potential of this isoformswitching to impact the retinal vasculature is not clear, particularly in primary human retinal endothelial cells, which are important targets of VEGFA. We do not know how these two isoforms compare in their ability to activate key intracellular signalling pathways (MAPK, AKT) or alter VEGFA-target gene expression in primary human endothelial cells from the neural retina. Methods: Effects of saturating amounts of both VEGFA 165 isoforms (a/b) on the rat retinal vasculature were compared using intravitreal injection, fluorescein-angiography and Optical Coherence Tomography to monitor primary vein dilation and retinal edema. Full dose-response curves for the activation of MAPK (ERK1/2), AKT and VEGFR2 were determined using direct in-cell western assays of primary Human Retinal Microvascular Endothelial Cells (HRMECs). Differences in dose-response effects on gene expression markers related to endothelial cell / leukocyte adhesion (ICAM1, VCAM1 and SELE ) and tight-junctions (CLDN5 and OCLN ) were tested by quantitative-PCR. Results: In rats, dilation of primary retinal veins and edema could be induced within 24 hours by intravitreal injection of a saturating dose of either isoform. In HRMECs, activation dose-response analysis revealed much stronger activation of MAPK, AKT and VEGFR2 by the a-isoform at lower doses. While similar maximum activation of VEGFR2 and MAPK could be achieved by both isoforms at higher doses, maximum activation of AKT by the b-isoform was only half that observed for the a-isoform. At the level of gene expression, VEGFA 165 a was also more effective 3 at increasing expression of ICAM1, VCAM1 and SELE and decreasing expression of CLDN5 and OCLN at intermediate and high doses in primary HRMECs. Conclusions: VEGFA 165 a maximally activated MAPK and AKT in HRMECs at lower concentrations where VEGFA 165 b had little effect. The timing for maximal activation of MAPK was similar for both isoforms in HRMECs, which is different from non-retinal endothelial cells. While the dose-responses for VEGFR2 and MAPK activation had similar maximums with both isoforms, there were large differences between the isoforms in their effects on endothelial cell gene expression even at a high dose. The shifts of VEGFA 165 expression from mostly b-isoform to mostly a-isoform, as reported in some human retinal vascular diseases, could potentially impact the activation of intracellular signalling and VEGFA target gene expression in endothelial cells of the human neural retina. Receptor-2 (VEGFR2). A seminal analysis of the vitreous fluids of patients with diabetic retinopathy established the presence of elevated VEGF concentrations associated with this and other conditions 1 . That study contributed to the eventual development of intravitreal VEGFblocking drugs to treat neovascularization and edema in AMD, DR, and the current exploration of their use for ROP 2-5 .
Introduction
Vascular Endothelial Growth Factor-A-165 (VEGFA 165 ) is the isoform of VEGF that is primarily responsible for driving retinal vascular pathology in diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinopathy of prematurity (ROP), through activation of VEGF 5 VEGFA 165 and VEGFA 121 have similar binding affinities for VEGFR2, VEGFA 121 activates VEGFR2 less strongly than VEGFA 165 . This was attributed to VEGFA 165 's ability to form a larger complex of multiple VEGFR2 dimers with additional involvement of Neuropilin-1 as a coreceptor (Whitaker et al., 2001) .
The a-and b-isoforms differ in the sequence of their C-terminal six amino acids 10 . This difference renders the b-isoform incapable of bringing the co-receptor Neuropilin-1 into a receptor/ligand complex with VEGFR2 [12] [13] [14] . Similar to VEGFA 121 , which only binds to VEGFR2, VEGFA 165 b is less angiogenic than the a-isoform, VEGFA 165 a 10, 15, 16 . VEGFA 165 b has similar VEGFR2-binding affinity as VEGFA 165 a in Human Umbilical Vein Endothelial Cells (HUVECs). The b-isoform also displays weaker activation of VEGFR2 and ERK1/2 than the aisoform in transfected porcine aortic endothelial (PAE) cells 17 . Perrin et al. (2005) , detected a switch from mostly b-isoform to mostly a-isoform in the vitreous of patients with active diabetic retinopathy 18 . A similar shift, from VEGFA 165 b to VEGFA 165 a, was reported from analysis of vitreous humor of young patients with ROP 19 . An equivalent isoform switching of murine VEGFA 164 a to VEGFA 164 b occurs in a mouse model of oxygen-induced retinopathy 20 .
Intravitreal injection of VEGFA 165 b was reported to reduce the leakiness of the retinal vasculature in one-week diabetic rats which suggested that the b-isoform could be beneficial by sequestering VEGFR2 signalling in a lower activated state 21 . Here, we report that a higher, likey saturating, dose of VEGFA 165 b could dilate primary retinal veins to the same extent as VEGFA 165 a in the normal rat eye. Yet, both of these observations are compatible if there is a significant difference in the dose response effects of the two isoforms on retinal endothelial cells. 6 While studies using transfected cells or non-retinal endothelial cells, such as HUVECs, indicate that the b-isoform is relatively less activating of VEGFR2 and ERK1/ERK2 than the a-isoform, we wished to determine if this is true for endothelial cells derived from the retina and also from the human retina.
We hypothesized that there is a significant difference in the dose-reponse for activation of retinal endothelial cells between the a-and b-isoforms of VEGFA 165 . Furthermore we hypothesized that the a-isoform is a significantly stronger activator of VEGFA signalling pathways within this cell type. To address these hypotheses, we determined the dose-reponse for activation of MAPK (ERK1/2), AKT and VEGFR2 in primary HRMECs for both isoforms of VEGFA 165 . Our results demonstrate that there is a significant dose-response difference in the ability of these two isoforms to activate intracellular signalling kinases and that these doseresponse differences propagate to large differences in VEGF-target gene expression in primary human retinal endothelial cells.
Methods

Cell Culture and Antibodies: Human Retinal Microvascular Endothelial Cells (HRMEC) and
Attachment Factor were purchased from Cell Systems (Kirkland, WA). EndoGRO-MV Complete media kit was obtained from Millipore (Burlington, MA). EndoGro basal medium was supplemented with rhEGF, L-Glutamine, Heparin Sulfate and Ascorbic Acid according to the kit instructions. Additionally, supplementation with FBS and Hydrocortisone Hemisuccinate (1µg/ml) was dependent upon the assay requirements. Recombinant human VEGFA 165 a and 7 VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN). Odyssey Blocking Buffer and an Odyssey Infrared Imager were purchased from LI-COR Biosciences (Lincoln, NE). The antibodies used for in situ labeling of HMRECs (In Cell Westerns, ICW) and Western blotting are summarized in Table 1 . Mini Protean TGX gels were purchased from Bio-Rad (Hercules, CA). 
Analysis of rat retinal edema and primary retinal vein diameter in vivo: Spectral Domain Optical
Coherence Tomography (SD-OCT) was utilized to measure changes in retina thickness in vivo, 
Immunoblotting of activated MAPK and AKT in HRMECs: Primary Human Retinal
Microvascular Endothelial Cells (HRMECs, genotype XY) were obtained from Cell Systems (Kirkland, WA, Catalog number: ACBRI-181). HRMECs were grown in 100mm dishes that had been pre-coated with Attachment Factor (Cell Systems, WA). Media was EndoGRO (No VEGF, Millipore Sigma, Burlington, MA) with 5% FBS to establish confluency. When cells were confluent, the media was replaced with fresh media with or without VEGFA 165 isoforms. After incubation for 10 minutes, the cells were washed with ice cold PBS and the dishes were scraped to detach the cells. The cell suspension was then centrifuged at 1000 X g for 5 minutes and the cells were reconstituted in RIPA cell-lysis buffer (150 mM NaCl, 1% Triton-X-100, 0.1% SDS, 50 mM Tris, pH 8.0, 10 mM Sodium Fluoride, 1 mM Sodium Orthovanadate and complete Protease inhibitor cocktail (1 tablet/10 ml)). The cells were then sonicated or vortexed every 10 minutes while kept on ice for 30 minutes. The cell lysate was collected after centrifuging at 14,000 X g for 15 minutes at 4°C. The protein concentration was then measured using Pierce BCA Protein Assay (Thermo Scientific). The samples were then prepared with Laemmli sample buffer and loaded onto a (4-15%) gradient gels for SDS-PAGE electrophoresis. After electrophoresis the gels were equilibrated in cold transfer buffer and then transferred to PDVF membranes overnight. The membranes were then blocked with Odyssey blocking buffer and incubated with appropriates rabbit primary antibodies (Table-1 ) along with mouse monoclonal 11 Actin antibody which was used for normalization. After washing with PBS, 0.1% tween-20 (4 X 5 min), the membranes were incubated with secondary antibodies (Goat Anti-rabbit IRDye680
and Goat Anti-mouse IRDye800CW) for 30-60 minutes. They were then washed and scanned on an Odyssey Infrared imager (Li-Cor, Lincoln, NE). Reactions were run on either an Mx3000P real-time PCR system using the MxPro software, or an AriaMx Real-time PCR System using the AriaMx HRM QPCR Software (Agilent, Santa Clara, CA). Gene expression assays were evaluated for high PCR efficiency using a dilution series of HMREC cDNA to ensure validity of using the delta-delta Ct method for comparing relative gene expression. Each replicate reaction was internally normalized relative to endogenous TBP gene expression. The specific assay probe sets used for gene expression analysis are listed in Table 2 .
Dose-response analysis of intracellular signaling in primary HMRECs
Table 2. Taqman gene expression probes for HRMEC gene expression.
RESULTS
Comparing Effects of saturating VEGFA 165 a and VEGFA 165 b on the Retinal Vasculature In Vivo:
The Long Evans's rat strain was used for two reasons. First, to avoid the use of non-pigmented eyes, which may experience additional contributions from oxidation damage. Second, to allow the use of fluorescein angiography (FA) for imaging the retinal vasculature, which is not possible with non-pigmented eyes. Intra-vitreal injection of VEGFA 165 isoforms were employed, as this method was used previously to demonstrate that VEGFA disrupts the blood retinal barrier and that VEGFA-blockade could be employed as a therapeutic strategy [22] [23] [24] [25] [26] In addition, the maximum activation of AKT generated by the b-isoform was less than half that obtained from treatment with the a-isoform. Repetition of the experiment confirmed similar relative responses. Maximum activation of the receptor was very fast and likely within less than a few minutes (as quickly as cells could be processed for treatment and fixation). Five and ten minute experiments were similar in relative response, so ten minutes were used for the dose-response experiment shown. (Figure-10a ). VEGFA 165 a treatment achieved maximum activation by about 500 pM whereas the b-isoform caused little if any activation at that dose. The ED 50 for activation by the aisoform was 254 pM compared to 1192 pM for the b-isoform. Furthermore, the maximum activation by the b-isoform was 73% of that obtained by the a-isoform. Again, this relative pattern was confirmed by a repeated experiment (data not shown).
Isoform Effects on Gene Expression: Leukocyte Docking and Tight-Junction Proteins:
After establishing that the b-isoform was also capable of activating both MAPK and AKT, we examined several gene expression markers from 1 to 24 hours after VEGFA 165 treatment using a dose that provided for maximal activation of singalling by either isoform (5,300 pM). We examined three genes important for the activation of leukocyte-endothelial cell adhesion: ICAM1,
Selectin-E, and VCAM1 (Figure-11a , c, e). All three of these genes displayed increased expression after treatment with either isoforms of VEGFA 165 with maximum changes at the 6 hour point. These trends were confirmed by repeated experiments. ICAM1's increasing expression trend was the same but not always maximum at 6 hours, sometimes later by 24 hours (data not shown).
Guided by our kinase activation dose-response data for VEGFR2, MAPK and AKT, we selected a low (100 pM), intermediate (1000 pM) and high (5,000 pM) dose to test for doseresponse differences in the effects on endothelial cell gene expression. (Figure-11b , d, f). We pM dose. 20 We also compared the effects VEGFA 165 isoforms on the expression of genes encoding the tight-junction proteins Claudin-5 and Occludin (Figure-12 ). Both isoforms of VEGFA 165 reduced the expression of these genes with a stronger effect on Claudin-5 gene expression.
Expression of both genes recovered by 24 hours (Figure-12a, c ). Comparing the low, intermediate and high doses at 6 hours, VEGFA 165 b was also less effective at suppressing the expression of Claudin-5 and Occludin compared to VEGFA 165 a, even at the highest dose tested (Figure-12b, d) .
DISCUSSION
While the role of VEGFA in vascular development, tumorgenesis and hypoxia has been studied for over two decades, less studies have differentiated the functional contributions of different VEGFA size-isoforms nor the a-and b-isoforms. More recently, isoform-specific analysis found that most VEGFA 165 in normal vitreous was the b-isoform, with the ratio changing to mostly a-isoform in eyes with active diabetic retinopathy and ROP 18, 19 . The a-and b-isoforms are derived from the VEGFA gene through alternative splicing of the pre-mRNA.
Phosphorylation of the ASF/SF2 splice-factor by the SR protein kinases (SRPK1/2) regulates alternate splicing of exon 8 28 We started our investigations by using intravitreal injections of a saturating dose of either isoform in a pigmented rat model to determining if the b-isoform can affect the retinal vasculature similar to the a-isoform. We found that both isoforms of VEGFA 165 could dilate primary retinal veins, an effect previously observed for VEGFA 165 a during studies that established it as a key disruptor of the blood-retinal barrier 29 . We saw no loss of capilary perfusion comparing before and after angiography images of treated eyes and the dilation affected primary veins that lack smooth muscle. We suggest the dilation occured when tight junctions between endothelial cells While VEGFA 165 b does not bind the Neuropilin-1 co-receptor, it does bind to VEGFR2 with the similar affinity as the a-isoform 17, 34 . Previous studies reported that the b-isoform activated VEGFR2 and MAPK more weakly than the a-isoform and maximum activation of MAPK was more delayed with the b-isofom in porcine aortic endothelial cells (PAECs) and bovine aortic endothelial cells 17, 35 , using a dose of 2,600 pM. Another study of human pulmonary microvascular endothelial cells (HPMECs) found that the a-isoform was a stronger activator of VEGFR2 and MAPK (ERK1/2) than the b-isoform at a dose of 20 ng/ml (1000 pM) 36 . So we also began with immunoblotting to examine the activation of MAPK and AKT in primary HRMECs. We found that both MAPK and AKT were activated to a similar extent using a higher dose (100 ng/ml, 5,300 pM) in primary HRMECs. We found that both MAPK and AKT were activated less by the b-isoform at the lower dose (20 ng/ml, 1000 pM) (data not shown).
With this preliminary guidance from Western blotting, we developed in-cell-western (ICW) assays to measure activation of these kinases in situ. This enabled us to explore activation dose-response for MAPK and AKT in primary HRMECs. As previously noted we lacked this information for retinal endothelial cells. Furthermore, activation of these kinases are not typically measured over a full range of doses. Our dose-response curves confirmed that there are substantial differences in the activation of both MAPK and AKT by the two isoforms of VEGFA 165 in primary HRMECs. In the case of MAPK, the ED 50 dose (Effective Dose for 50% maximal activation) was more than 800 pM lower for VEGFA 165 a compared to the b-isoform. For AKT, the ED 50 was two-fold greater for the b-isoform compared to the a-isoform. The activation of AKT by b-isoform remained subtanially less than that from the a-isoform over the entire dose-response range. In contrast to MAPK activation, the time to maximum activation of AKT was earlier with the a-isoform (15 minutes) compared to the b-isoform (30 minutes).
Another difference from MAPK was that the maximum activation of AKT obtained with the bisoform was only half of the maximum response from the a-isoform. This was different from human pulmonary endothelial cells where AKT activation is the same with both isoforms at a dose of 20 ng/ml (1000pM) 36 . These difference reveal that nuances of VEGF-mediated signaling should not be considered universal between different sub-types of vascular endothelial cells.
The hypothesis that the differences in the activation of MAPK and AKT also begin with activation of the receptor in retinal endothelial cells was confirmed by our dose-response analysis for activation of VEGFR2. Again, the a-isoform was far more potent for activating VEGFR2 compared to the b-isoform at lower doses. Altogether, our dose-response curves for the activation of VEGFR2, MAPK, and AKT are consistent with the model proposed by Whitaker et al.,
wherein the a-isoform activates VEGFR2 more intensely when it can bind the co-receptor
Neuropilin-1 to form a larger activation complex comprised of more VEGFR2 and Neuropilin-1 subunits 37 .
We also found that VEGFA 165 b could affect the expression of genes also regulated by had very little effect. Furthermore the b-isoform could not increase the expression of these three genes to the level observed with the a-isoform, even at the higher dose. VEGFA 165 b was also less effective than the a-isoform at suppressing the expression of the tight-junction structural genes, Claudin-5 and Occludin. We concluded that there were significant dose-response differences in the regulation of VEGFA-target genes, with the a-isoform proving to be the stronger affector of gene expression changes in primary HRMECs. 
